title: Effectiveness of antiplatelet therapy in atherosclerotic disease: comparing the ASA low-response prevalence in CVD, CAD and PAD.
abstract: Although acetylsalicylic acid (ASA, aspirin) reduces the risk of ischemic events in patients with atherosclerosis, a substantial number of incidents continue to occur. As only limited data exist we evaluated the antiplatelet effectiveness of ASA in patients with different manifestations of atherosclerosis as in cerebrovascular, coronary artery and peripheral arterial disease (CVD, CAD, PAD). For the evaluation of the antiplatelet effectiveness of ASA we used whole blood aggregometry (Chrono-log Model 590). The patients in the different subgroups received ASA 100, 200 or 500 mg daily. We analysed 737 consecutive patients: 47.5 % with CVD, 33.6 % with CAD, and 18.9 % with PAD. We identified 28.0 % of the CVD, 18.1 % of the CAD and 21.6 % of the PAD patients to be ASA low-responder (ALR). Comparing subgroups treated with 100 mg ASA, 36.4 % were ALR in the CVD group as were 13.1 % of the CAD and 21.6 % of the PAD patients. Multivariate regression analysis revealed an odds ratio for being ALR of 4.50 (95 % confidence interval (CI) 1.70-11.9) when 100 mg and of 2.97 (95 % CI 1.58-5.60) when 200 mg ASA was taken compared to a dose of 500 mg. Despite the proven benefits of antiplatelet therapy in the secondary prevention of atherosclerotic disease, current antiplatelet management is suboptimal as up to 36 % of patients failed to achieve an adequate platelet inhibitory effect. Our findings may explain, at least in part, the high rates of cardiovascular events observed in the course of atherothrombotic disease and support the need to improve antiplatelet therapy.
authors.affiliation: Department of Neurology, St. Josef-Hospital, Ruhr University Bochum, Gudrunstraße 56, 44791, Bochum, Germany, saskia.m.meves@rub.de.
authors.forename: Saskia H
authors.initials: SH
authors.lastname: Meves
authors.forename: Thomas
authors.initials: T
authors.lastname: Hummel
authors.forename: Heinz G
authors.initials: HG
authors.lastname: Endres
authors.forename: Nora
authors.initials: N
authors.lastname: Mayböck
authors.forename: Andreas F C
authors.initials: AF
authors.lastname: Kaiser
authors.forename: Kay D
authors.initials: KD
authors.lastname: Schröder
authors.forename: Katja
authors.initials: K
authors.lastname: Rüdiger
authors.forename: Ursula
authors.initials: U
authors.lastname: Overbeck
authors.forename: Achim
authors.initials: A
authors.lastname: Mumme
authors.forename: Andreas
authors.initials: A
authors.lastname: Mügge
authors.forename: Horst
authors.initials: H
authors.lastname: Neubauer
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001241:Aspirin / Q000008:administration & dosage*; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000453:epidemiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D058729:Peripheral Arterial Disease / Q000188:drug therapy / Q000453:epidemiology; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D015995:Prevalence; D020521:Stroke / Q000188:drug therapy / Q000453:epidemiology
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin
references.citation: J Vasc Surg. 2010 Jan;51(1):242-51
references.pmid: 19954922
references.citation: BMC Res Notes. 2011 Apr 05;4:106
references.pmid: 21466682
references.citation: J Neurol. 2003 Jan;250(1):63-6
references.pmid: 12527994
references.citation: Thromb Haemost. 2010 Aug;104(2):279-86
references.pmid: 20508896
references.citation: Lancet. 1996 Nov 16;348(9038):1329-39
references.pmid: 8918275
references.citation: Thromb Haemost. 2009 Aug;102(2):404-11
references.pmid: 19652893
references.citation: JAMA Neurol. 2013 Feb;70(2):208-13
references.pmid: 23165316
references.citation: J Transl Med. 2008 Aug 29;6:46
references.pmid: 18759978
references.citation: Lancet. 2005 Nov 19;366(9499):1773-83
references.pmid: 16298214
references.citation: BMJ. 2008 Jan 26;336(7637):195-8
references.pmid: 18202034
references.citation: JAMA. 2006 Jan 11;295(2):180-9
references.pmid: 16403930
references.citation: Thromb Haemost. 2012 Jan;107(1):69-79
references.pmid: 22159509
references.citation: Thromb Res. 2006;118(5):619-26
references.pmid: 16356539
references.citation: Curr Vasc Pharmacol. 2012 Jul;10(4):494-505
references.pmid: 22272895
references.citation: Platelets. 2009 Sep;20(6):386-90
references.pmid: 19811222
references.citation: Thromb Res. 1993 Sep 1;71(5):397-403
references.pmid: 8236166
references.citation: Herz. 2008 Jun;33(4):287-96
references.pmid: 18581078
references.citation: Circulation. 2003 Aug 5;108(5):542-7
references.pmid: 12874188
references.citation: J Thromb Haemost. 2012 Jul;10(7):1220-30
references.pmid: 22471290
references.citation: Cardiol J. 2009;16(6):535-44
references.pmid: 19950090
references.citation: J Thromb Haemost. 2010 Mar;8(3):613-5
references.pmid: 19995405
references.citation: J Clin Pharmacol. 2008 Mar;48(3):335-43
references.pmid: 18223144
references.citation: Cerebrovasc Dis. 2008;25(4):355-61
references.pmid: 18305387
references.citation: Diabetes. 2007 Dec;56(12):3014-9
references.pmid: 17848625
references.citation: Dtsch Arztebl Int. 2008 Nov;105(45):769-75
references.pmid: 19578408
references.citation: Vasc Med. 2010 Aug;15(4):259-65
references.pmid: 20724374
references.citation: Eur Heart J. 2009 Oct;30(19):2318-26
references.pmid: 19720633
references.citation: Eur Heart J. 2009 Feb;30(4):426-35
references.pmid: 19174428
references.citation: Dan Med J. 2012 Sep;59(9):B4506
references.pmid: 22951204
references.citation: Platelets. 2009 May;20(3):199-205
references.pmid: 19437338
references.citation: Thromb Res. 2012 Jan;129(1):56-61
references.pmid: 21917303
references.citation: Thromb Haemost. 1997 Sep;78(3):1003-7
references.pmid: 9308744
references.citation: Br J Haematol. 2004 Jun;125(6):777-87
references.pmid: 15180868
references.citation: Stroke. 2002 Apr;33(4):901-6
references.pmid: 11935034
references.citation: Aliment Pharmacol Ther. 1997 Oct;11(5):899-906
references.pmid: 9354198
references.citation: MedGenMed. 2007 Sep 19;9(3):58
references.pmid: 18092064
references.citation: J Cardiovasc Pharmacol. 2009 Aug;54(2):163-8
references.pmid: 19568178
references.citation: Curr Med Res Opin. 2009 Nov;25(11):2631-41
references.pmid: 19769467
references.citation: Ann N Y Acad Sci. 2010 Oct;1207:11-7
references.pmid: 20955420
references.citation: Eur J Cardiovasc Prev Rehabil. 2010 Aug;17(4):424-30
references.pmid: 20555265
references.citation: Clin Chem. 2007 Apr;53(4):614-9
references.pmid: 17332149
references.citation: Thromb Haemost. 2011 Feb;105(2):209-10
references.pmid: 21136021
references.citation: J Am Coll Cardiol. 2003 Mar 19;41(6):961-5
references.pmid: 12651041
references.citation: J Vasc Surg. 2007 Sep;46(3):485-90
references.pmid: 17826235
references.citation: Eur Heart J. 2004 Jul;25(14):1197-207
references.pmid: 15246637
references.citation: Lancet. 2009 May 30;373(9678):1849-60
references.pmid: 19482214
references.citation: Eur J Cardiovasc Prev Rehabil. 2004 Oct;11(5):394-402
references.pmid: 15616412
references.citation: Heart. 2011 Apr;97(8):660-7
references.pmid: 21357372
references.citation: Am J Cardiol. 2009 Jul 15;104(2):227-33
references.pmid: 19576352
references.citation: Diab Vasc Dis Res. 2012 Oct;9(4):245-55
references.pmid: 22508698
references.citation: Thromb Haemost. 2010 Apr;103(4):841-8
references.pmid: 20135063
references.citation: Heart. 2010 Mar;96(5):368-71
references.pmid: 19910291
references.citation: Am J Cardiol. 2011 Feb 1;107(3):339-42
references.pmid: 21256995
references.citation: Stroke. 2003 Jun;34(6):1412-8
references.pmid: 12764232
references.citation: BMC Med. 2011 Jan 12;9:3
references.pmid: 21226927